Agendia BV hopes adoption and reimbursement for its MammaPrint 70-gene breast cancer risk-of-recurrence test will get a boost from new American Society of Clinical Oncology guidelines (ASCO) that specifically recommend MammaPrint.
A focused update to ASCO's practice guidelines on biomarkers to guide decisions on adjuvant systemic therapy for women with early stage invasive breast cancer, published in the Journal...